<table border="single" id="id_ae2279a9-65b7-4fd8-bb16-c89bd6699605" width="441.000" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="30.6%"></col>
<col width="26.5%"></col>
<col width="42.9%"></col>
<tbody>
<tr id="id_836990dc-afa8-440c-9be9-abbf35363016">
<td align="center" stylecode="Botrule Toprule Rrule Lrule" valign="top">Concomitant Drug Class: Drug Name</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Effect on Concentration of Amprenavir or Concomitant Drug</td>
<td align="center" stylecode="Botrule Rrule" valign="top">Clinical Comment</td>
</tr>
<tr id="id_178d00db-5978-48a2-bb45-08463820e18b">
<td align="center" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="italics">HIV-Antiviral Agents</content>
</content>
</td>
</tr>
<tr id="id_5ad223eb-d3ef-4959-90b4-85d0ce6dec80">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content> Efavirenz<sup>a</sup>
</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↓Amprenavir</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
↓Amprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Appropriate doses of the combinations with respect to safety and efficacy have not been established. </paragraph>
An additional 100 mg/day (300 mg total) of ritonavir is recommended when efavirenz is administered with LEXIVA/ritonavir once daily. No change in the ritonavir dose is required when efavirenz is administered with LEXIVA plus ritonavir twice daily. </td>
</tr>
<tr id="id_cf21fc22-7edb-4683-80d6-195c8d49f2cf">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Non-nucleoside reverse transcriptase inhibitor:</content>
</paragraph>
Nevirapine<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↓Amprenavir </paragraph>
<paragraph>↑Nevirapine</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>↓Amprenavir</paragraph>
<paragraph>↑Nevirapine</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Coadministration of nevirapine and LEXIVA without ritonavir is not recommended.</paragraph>
<paragraph>No dosage adjustment required when nevirapine is administered with LEXIVA/ritonavir twice daily. </paragraph>
The combination of nevirapine administered with LEXIVA/ritonavir once-daily regimen has not been studied.</td>
</tr>
<tr id="id_50416c88-7706-42b2-9362-dc6d2624766b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">HIV protease inhibitor:</content>
</paragraph>
Atazanavir<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>Interaction has not been evaluated.</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>↓Atazanavir</paragraph>
↔Amprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of the combinations with respect to safety and efficacy have not been established.</td>
</tr>
<tr id="id_f9216847-50a4-4c8e-821c-4a4346f00483">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">HIV protease inhibitors:</content>
</paragraph>
Indinavir<sup>a</sup>, nelfinavir<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↑Amprenavir</paragraph>
<paragraph>Effect on indinavir and nelfinavir is not well established.</paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content> Interaction has not been evaluated.</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of the combinations with respect to safety and efficacy have not been established. </td>
</tr>
<tr id="id_0fbb079b-d905-4d31-a046-0f9abdf44f8b">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">HIV protease inhibitors:</content>
</paragraph>
Lopinavir/ritonavir<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓Amprenavir</paragraph>
<paragraph>↓Lopinavir</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">An increased rate of adverse events has been observed. Appropriate doses of the combinations with respect to safety and efficacy have not been established.</td>
</tr>
<tr id="id_a732c670-ba5b-4db4-8533-a8f5f596b817">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">HIV protease inhibitor:</content>
</paragraph>
Saquinavir<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↓Amprenavir</paragraph>
<paragraph>Effect on saquinavir is not well established.</paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content> Interaction has not been evaluated.</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Appropriate doses of the combination with respect to safety and efficacy have not been established.</td>
</tr>
<tr id="id_cfb71b76-7f4a-4451-b832-f2b6407d7a41">
<td align="center" colspan="3" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">
<content stylecode="italics">Other Agents</content>
</content>
</td>
</tr>
<tr id="id_03fa5606-c49e-451d-9e11-eaaa21d590b3">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Antiarrhythmics:</content>
</paragraph>
Amiodarone, bepridil, lidocaine (systemic), and quinidine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Antiarrhythmics</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use with caution. Increased exposure may be associated with life-threatening reactions such as cardiac arrhythmias. Therapeutic concentration monitoring, if available, is recommended for antiarrhythmics. </td>
</tr>
<tr id="id_56e1f464-eadc-4c54-8a73-137b97406832">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Anticoagulant:</content>
</paragraph>
Warfarin</td>
<td align="left" stylecode="Botrule Rrule" valign="top"></td>
<td align="left" stylecode="Botrule Rrule" valign="top">Concentrations of warfarin may be affected. It is recommended that INR (international normalized ratio) be monitored. </td>
</tr>
<tr id="id_53e12f24-4ec5-49e2-878f-7459d4ec4444">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Anticonvulsants:</content>
</paragraph>
<paragraph>Carbamazepine, phenobarbital, phenytoin</paragraph>
<paragraph>Phenytoin<sup>a</sup>
</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↓Amprenavir</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>↑Amprenavir</paragraph>
<paragraph>↓Phenytoin</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Use with caution. LEXIVA may be less effective due to decreased amprenavir plasma concentrations in patients taking these agents concomitantly. </paragraph>
Plasma phenytoin concentrations should be monitored and phenytoin dose should be increased as appropriate. No change in LEXIVA/ritonavir dose is recommended.</td>
</tr>
<tr id="id_f3865d1c-5b15-407b-893d-763baec0e858">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Antidepressant:</content>
</paragraph>
Paroxetine, trazodone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↓Paroxetine</paragraph>
↑Trazodone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Coadministration of paroxetine with LEXIVA/ritonavir significantly decreased plasma levels of paroxetine. Any paroxetine dose adjustment should be guided by clinical effect (tolerability and efficacy).</paragraph>
Concomitant use of trazodone and LEXIVA with or without ritonavir may increase plasma concentrations of trazodone. Adverse events of nausea, dizziness, hypotension, and syncope have been observed following coadministration of trazodone and ritonavir. If trazodone is used with a CYP3A4 inhibitor such as LEXIVA, the combination should be used with caution and a lower dose of trazodone should be considered.</td>
</tr>
<tr id="id_e60a472c-94dc-4efd-a39c-f78e2e5faaa9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Antifungals:</content>
</paragraph>
Ketoconazole<sup>a</sup>, itraconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Ketoconazole</paragraph>
↑Itraconazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Increase monitoring for adverse events. </paragraph>
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>Dose reduction of ketoconazole or itraconazole may be needed for patients receiving more than 400 mg ketoconazole or itraconazole per day. </paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
High doses of ketoconazole or itraconazole (&gt;200 mg/day) are not recommended.</td>
</tr>
<tr id="id_dbbfb0dd-8dc8-48e3-a2a7-8cbf26a9de67">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Antimycobacterial:</content>
</paragraph>
Rifabutin<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Rifabutin and rifabutin metabolite</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>A complete blood count should be performed weekly and as clinically indicated to monitor for neutropenia. </paragraph>
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>A dosage reduction of rifabutin by at least half the recommended dose is required. </paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
Dosage reduction of rifabutin by at least 75% of the usual dose of 300 mg/day is recommended (a maximum dose of 150 mg every other day or 3 times per week).</td>
</tr>
<tr id="id_4cd2dadf-3944-4283-bd79-e933e17075e0">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Benzodiazepines: </content>
</paragraph>
Alprazolam, clorazepate, diazepam, flurazepam</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Benzodiazepines</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Clinical significance is unknown. A decrease in benzodiazepine dose may be needed. </td>
</tr>
<tr id="id_34c343a9-abc1-42ca-b055-30eab073d392">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Calcium channel blockers:</content>
</paragraph>
Diltiazem, felodipine, nifedipine, nicardipine, nimodipine, verapamil, amlodipine, nisoldipine, isradipine</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Calcium channel blockers</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use with caution. Clinical monitoring of patients is recommended. </td>
</tr>
<tr id="id_e1ae828e-d874-4120-bb3d-729b867bc5d8">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<content stylecode="bold">Corticosteroid:</content> Dexamethasone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓Amprenavir</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use with caution. LEXIVA may be less effective due to decreased amprenavir plasma concentrations. </td>
</tr>
<tr id="id_9a3369f0-bbdc-4c65-a435-62296156b754">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Histamine H<sub>2</sub>-receptor antagonists:</content>
</paragraph>
<paragraph>Cimetidine, famotidine, nizatidine, ranitidine<sup>a</sup>
</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↓Amprenavir</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
Interaction not evaluated</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use with caution. LEXIVA may be less effective due to decreased amprenavir plasma concentrations.</td>
</tr>
<tr id="id_bbf5d1b2-72d0-490f-b350-dfc3dd0f3829">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">HMG-CoA reductase inhibitor:</content>
</paragraph>
Atorvastatin<sup>a</sup>, rosuvastatin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Atorvastatin</paragraph>
↑Rosuvastatin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Use the lowest possible dose of atorvastatin or rosuvastatin with careful monitoring, or consider other HMG-CoA reductase inhibitors such as fluvastatin or pravastatin. </td>
</tr>
<tr id="id_272cfd2f-e244-4cbf-9675-6b3470ff195c">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Immunosuppressants:</content>
</paragraph>
Cyclosporine, tacrolimus, rapamycin</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↑Immunosuppressants</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Therapeutic concentration monitoring is recommended for immunosuppressant agents. </td>
</tr>
<tr id="id_f87458d6-303e-47b8-923e-cb9169ccad98">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Inhaled/nasal steroid:</content>
</paragraph>
Fluticasone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↑Fluticasone</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>↑Fluticasone</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Use with caution. Consider alternatives to fluticasone, particularly for long-term use.</paragraph>
May result in significantly reduced serum cortisol concentrations. Systemic corticosteroid effects including Cushings syndrome and adrenal suppression have been reported during postmarketing use in patients receiving ritonavir and inhaled or intranasally administered fluticasone. Coadministration of fluticasone and LEXIVA/ritonavir is not recommended unless the potential benefit to the patient outweighs the risk of systemic corticosteroid side effects.</td>
</tr>
<tr id="id_c3120f40-0efe-4151-bab5-604c2d79daa1">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Narcotic analgesic:</content>
</paragraph>
Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">↓Methadone</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Data suggest that the interaction is not clinically relevant; however, patients should be monitored for opiate withdrawal symptoms.</td>
</tr>
<tr id="id_c18eb569-0592-4cc6-baa6-2bfaa73c4ec9">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Oral contraceptives:</content>
</paragraph>
Ethinyl estradiol/norethin-drone<sup>a</sup>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↓Amprenavir</paragraph>
<paragraph>↓Ethinyl estradiol</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>↓Ethinyl estradiol</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>Alternative methods of non-hormonal contraception are recommended.</paragraph>
<paragraph>May lead to loss of virologic response. <sup>*</sup>
</paragraph>
Increased risk of transaminase elevations. No data are available on the use of LEXIVA/ritonavir with other hormonal therapies, such as hormone replacement therapy (HRT) for postmenopausal women.</td>
</tr>
<tr id="id_d5f67d15-24db-4d17-bfa3-dd517a5fb7d5">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">PDE5 inhibitors:</content>
</paragraph>
<paragraph>Sildenafil, tadalafil, vardenafil</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>↑Sildenafil</paragraph>
<paragraph>↑Tadalafil</paragraph>
<paragraph>↑Vardenafil</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>May result in an increase in PDE5 inhibitor-associated adverse events, including hypotension, visual changes, and priapism.</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>Sildenafil: 25 mg every 48 hours. </paragraph>
<paragraph>Tadalafil: no more than 10 mg every 72 hours. </paragraph>
<paragraph>Vardenafil: no more than 2.5 mg every 24 hours. </paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>Sildenafil: 25 mg every 48 hours.</paragraph>
<paragraph>Tadalafil: no more than 10 mg every 72 hours.</paragraph>
Vardenafil: no more than 2.5 mg every 72 hours.</td>
</tr>
<tr id="id_52826619-0c90-4232-acac-759241446e05">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Proton pump inhibitors:</content>
</paragraph>
<paragraph>Esomeprazole<sup>a</sup>, lansoprazole, omeprazole, pantoprazole, rabeprazole</paragraph>
</td>
<td align="left" stylecode="Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">LEXIVA:</content>
</paragraph>
<paragraph>↔Amprenavir</paragraph>
<paragraph>↑Esomeprazole</paragraph>
<paragraph>
<content stylecode="bold">LEXIVA/ritonavir:</content>
</paragraph>
<paragraph>↔Amprenavir</paragraph>
↔Esomeprazole</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Proton pump inhibitors can be administered at the same time as a dose of LEXIVA with no change in plasma amprenavir concentrations.</td>
</tr>
<tr id="id_16f2f686-97c3-4e38-8a28-4f1def26e4e7">
<td align="left" stylecode="Lrule Botrule Rrule" valign="top">
<paragraph>
<content stylecode="bold">Tricyclic antidepressants:</content>
</paragraph>
Amitriptyline, imipramine</td>
<td align="left" stylecode="Rrule" valign="top">↑Tricyclics</td>
<td align="left" stylecode="Botrule Rrule" valign="top">Therapeutic concentration monitoring is recommended for tricyclic antidepressants. </td>
</tr>
</tbody>
</table>